Exploring the role of oncolytic viruses in hepatobiliary cancers

Pavan Tenneti; Mitesh J. Borad; Hani M. Babiker

doi:10.2217/imt-2018-0048

Exploring the role of oncolytic viruses in hepatobiliary cancers

Pavan Tenneti, Mitesh J. Borad, Hani M. Babiker

Hematology/Oncology

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

The standard of care for early hepatobiliary cancers (HBC) includes surgical resection. Liver transplantations or locoregional therapies are beneficial in early hepatocellular carcinoma (HCC) under certain circumstances. Systemic treatments have some benefit in advanced HBC, though long-term prognosis remains poor. We evaluated the role of oncolytic viruses in the treatment of HBCs through a systematic literature review. The recombinant vaccinia virus JX-594 improved median survival in patients with local/metastatic HCC more strongly at high dose than at low dose (14.1 vs 6.7 months; p = 0.08) in a Phase II study. A Phase III study with JX-594 and sorafenib in advanced HCC is ongoing. No survival benefit in HCC was seen with two other recombinant adenoviruses (Ad-TK and DL1520). Several preclinical trials using oncolytic viruses in HBC showed promising results, warranting clinical studies.

Original language	English (US)
Pages (from-to)	971-986
Number of pages	16
Journal	Immunotherapy
Volume	10
Issue number	11
DOIs	https://doi.org/10.2217/imt-2018-0048
State	Published - Aug 2018

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Oncology

Access to Document

10.2217/imt-2018-0048

Cite this

@article{c9d41df6dff94a93a1bb035687cc4703,

title = "Exploring the role of oncolytic viruses in hepatobiliary cancers",

abstract = "The standard of care for early hepatobiliary cancers (HBC) includes surgical resection. Liver transplantations or locoregional therapies are beneficial in early hepatocellular carcinoma (HCC) under certain circumstances. Systemic treatments have some benefit in advanced HBC, though long-term prognosis remains poor. We evaluated the role of oncolytic viruses in the treatment of HBCs through a systematic literature review. The recombinant vaccinia virus JX-594 improved median survival in patients with local/metastatic HCC more strongly at high dose than at low dose (14.1 vs 6.7 months; p = 0.08) in a Phase II study. A Phase III study with JX-594 and sorafenib in advanced HCC is ongoing. No survival benefit in HCC was seen with two other recombinant adenoviruses (Ad-TK and DL1520). Several preclinical trials using oncolytic viruses in HBC showed promising results, warranting clinical studies.",

author = "Pavan Tenneti and Borad, {Mitesh J.} and Babiker, {Hani M.}",

note = "Publisher Copyright: {\textcopyright} 2018 Future Medicine Ltd.",

year = "2018",

month = aug,

doi = "10.2217/imt-2018-0048",

language = "English (US)",

volume = "10",

pages = "971--986",

journal = "Immunotherapy",

issn = "1750-743X",

publisher = "Future Medicine Ltd.",

number = "11",

}

TY - JOUR

T1 - Exploring the role of oncolytic viruses in hepatobiliary cancers

AU - Tenneti, Pavan

AU - Borad, Mitesh J.

AU - Babiker, Hani M.

PY - 2018/8

Y1 - 2018/8

N2 - The standard of care for early hepatobiliary cancers (HBC) includes surgical resection. Liver transplantations or locoregional therapies are beneficial in early hepatocellular carcinoma (HCC) under certain circumstances. Systemic treatments have some benefit in advanced HBC, though long-term prognosis remains poor. We evaluated the role of oncolytic viruses in the treatment of HBCs through a systematic literature review. The recombinant vaccinia virus JX-594 improved median survival in patients with local/metastatic HCC more strongly at high dose than at low dose (14.1 vs 6.7 months; p = 0.08) in a Phase II study. A Phase III study with JX-594 and sorafenib in advanced HCC is ongoing. No survival benefit in HCC was seen with two other recombinant adenoviruses (Ad-TK and DL1520). Several preclinical trials using oncolytic viruses in HBC showed promising results, warranting clinical studies.

AB - The standard of care for early hepatobiliary cancers (HBC) includes surgical resection. Liver transplantations or locoregional therapies are beneficial in early hepatocellular carcinoma (HCC) under certain circumstances. Systemic treatments have some benefit in advanced HBC, though long-term prognosis remains poor. We evaluated the role of oncolytic viruses in the treatment of HBCs through a systematic literature review. The recombinant vaccinia virus JX-594 improved median survival in patients with local/metastatic HCC more strongly at high dose than at low dose (14.1 vs 6.7 months; p = 0.08) in a Phase II study. A Phase III study with JX-594 and sorafenib in advanced HCC is ongoing. No survival benefit in HCC was seen with two other recombinant adenoviruses (Ad-TK and DL1520). Several preclinical trials using oncolytic viruses in HBC showed promising results, warranting clinical studies.

UR - http://www.scopus.com/inward/record.url?scp=85052554426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052554426&partnerID=8YFLogxK

U2 - 10.2217/imt-2018-0048

DO - 10.2217/imt-2018-0048

M3 - Review article

C2 - 29900755

AN - SCOPUS:85052554426

SN - 1750-743X

VL - 10

SP - 971

EP - 986

JO - Immunotherapy

JF - Immunotherapy

IS - 11

ER -

Exploring the role of oncolytic viruses in hepatobiliary cancers

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this